Health Care [ 12/12 ] | Pharmaceuticals [ 64/73 ]
NASDAQ | Common Stock
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States.
It operates through two segments, Therapeutics and Contract Research.
The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.
Its Contract Research segment provides laboratory services.
The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatment of atopic dermatitis and other dermatologic conditions; Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; Zunsemetinib (ATI-450), a mitogen-activated protein kinase-activated protein kinase 2 inhibitor under Phase 1b/2 trials for the treatment of metastatic breast cancer and pancreatic ductal adenocarcinoma; and ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in preclinical stage to treat various atopic, immunologic, and respiratory diseases, as well as an ITK selective inhibitor candidate for the treatment of autoimmune diseases.
Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 6, 25 | -0.12 Increased by +50.00% | -0.29 Increased by +58.62% |
| Feb 25, 25 | -1.01 Decreased by -4.95 K% | -0.38 Decreased by -169.33% |
| Nov 4, 24 | -0.11 Increased by +73.17% | -0.01 Decreased by -1.00 K% |
| Aug 7, 24 | -0.15 Increased by +64.29% | -0.20 Increased by +25.00% |
| May 7, 24 | -0.24 Increased by +40.00% | -0.29 Increased by +17.24% |
| Feb 27, 24 | -0.02 Increased by +95.12% | -0.34 Increased by +94.12% |
| Nov 6, 23 | -0.41 Decreased by -36.67% | -0.48 Increased by +14.58% |
| Aug 7, 23 | -0.42 Decreased by -35.48% | -0.45 Increased by +6.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 1.46 M Decreased by -39.32% | -15.09 M Increased by +10.96% | Decreased by -1.04 K% Decreased by -46.75% |
| Dec 31, 24 | 9.21 M Decreased by -47.58% | -96.55 M Decreased by -6.38 K% | Decreased by -1.05 K% Decreased by -12.25 K% |
| Sep 30, 24 | 4.35 M Decreased by -53.18% | -7.59 M Increased by +74.07% | Decreased by -174.55% Increased by +44.63% |
| Jun 30, 24 | 2.77 M Increased by +47.99% | -10.99 M Increased by +62.85% | Decreased by -397.18% Increased by +74.90% |
| Mar 31, 24 | 2.40 M Decreased by -5.14% | -16.94 M Increased by +35.83% | Decreased by -706.46% Increased by +32.36% |
| Dec 31, 23 | 17.57 M Increased by +126.62% | -1.49 M Increased by +95.52% | Decreased by -8.49% Increased by +98.02% |
| Sep 30, 23 | 9.28 M Decreased by -51.19% | -29.26 M Decreased by -37.83% | Decreased by -315.24% Decreased by -182.40% |
| Jun 30, 23 | 1.87 M Increased by +22.32% | -29.57 M Decreased by -77.38% | Decreased by -1.58 K% Decreased by -45.02% |